أعرض في EDS

Association between serum level soluble programmed cell death ligand 1 and prognosis in patients with non‐small cell lung cancer treated with anti‐PD ‐1 antibody

التفاصيل البيبلوغرافية
العنوان:	Association between serum level soluble programmed cell death ligand 1 and prognosis in patients with non‐small cell lung cancer treated with anti‐PD ‐1 antibody
المؤلفون:	Yuji Matsumoto, Yuichiro Ohe, Hidehito Horinouchi, Ryota Shibaki, Shuji Murakami, Noboru Yamamoto, Yasushi Goto, Shintaro Kanda, Yutaka Fujiwara, Tatsuya Yoshida
المصدر:	Thoracic Cancer
بيانات النشر:	Wiley, 2020.
سنة النشر:	2020
مصطلحات موضوعية:	non‐small cell lung cancer, Adult, Male, 0301 basic medicine, Pulmonary and Respiratory Medicine, medicine.medical_specialty, Lung Neoplasms, Multivariate analysis, soluble PD‐L1, Pembrolizumab, Antibodies, Monoclonal, Humanized, Gastroenterology, Programmed cell death ligand 1, 03 medical and health sciences, 0302 clinical medicine, Carcinoma, Non-Small-Cell Lung, Internal medicine, mental disorders, medicine, Humans, Anti‐PD‐1 antibody, In patient, Lung cancer, Aged, Aged, 80 and over, biology, business.industry, Hazard ratio, Original Articles, General Medicine, PD‐L1 TPS, Middle Aged, Prognosis, medicine.disease, Survival Analysis, 030104 developmental biology, Oncology, 030220 oncology & carcinogenesis, biology.protein, Original Article, Female, Nivolumab, Antibody, business
الوصف:	Background Programmed cell death ligand 1 (PD‐L1) is known to have soluble forms aside from its membrane‐bound forms. The aim of this study was to evaluate the predictive and prognostic values of serum soluble PD‐L1 (sPD‐L1) in patients with non‐small cell lung cancer (NSCLC) who were treated with anti‐PD‐1 antibody. Methods A total of 233 patients were enrolled in this study. We assessed the level of serum sPD‐L1 before anti‐PD‐1 antibody treatment (pembrolizumab or nivolumab) and evaluated the correlation with PD‐L1 expression on tumor cells, the response to anti‐PD‐1 antibody treatment, and patient outcome. Results The median serum sPD‐L1 concentration was 67.7 (range, 25 to 223) pg/mL. A weak correlation between serum sPD‐L1 and tumor PD‐L1 expression was observed. The disease control rate in the high sPD‐L1 group (≥90 pg/mL) was significantly lower than that in the low sPD‐L1 group ( The PFS and OS of the high sPD‐L1 group were significantly shorter than those of the low sPD‐L1 group. The high level of serum sPD‐L1 was independently associated with a shorter PFS and OS.
تدمد:	1759-7714 1759-7706
الوصول الحر:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::19fced2ae8c7ae9ecc4e68e52a492d5dTest https://doi.org/10.1111/1759-7714.13721Test
حقوق:	OPEN
رقم الانضمام:	edsair.doi.dedup.....19fced2ae8c7ae9ecc4e68e52a492d5d
قاعدة البيانات:	OpenAIRE

ResultId	1
Header	edsair OpenAIRE edsair.doi.dedup.....19fced2ae8c7ae9ecc4e68e52a492d5d 874 3 unknown 874.4638671875
PLink	https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....19fced2ae8c7ae9ecc4e68e52a492d5d&custid=s6537998&authtype=sso
FullText	Array ( [Availability] => 0 )
Items	Array ( [Name] => Title [Label] => Title [Group] => Ti [Data] => Association between serum level soluble programmed cell death ligand 1 and prognosis in patients with non‐small cell lung cancer treated with <scp>anti‐PD</scp> ‐1 antibody ) Array ( [Name] => Author [Label] => Authors [Group] => Au [Data] => <searchLink fieldCode="AR" term="%22Yuji+Matsumoto%22">Yuji Matsumoto</searchLink><br /><searchLink fieldCode="AR" term="%22Yuichiro+Ohe%22">Yuichiro Ohe</searchLink><br /><searchLink fieldCode="AR" term="%22Hidehito+Horinouchi%22">Hidehito Horinouchi</searchLink><br /><searchLink fieldCode="AR" term="%22Ryota+Shibaki%22">Ryota Shibaki</searchLink><br /><searchLink fieldCode="AR" term="%22Shuji+Murakami%22">Shuji Murakami</searchLink><br /><searchLink fieldCode="AR" term="%22Noboru+Yamamoto%22">Noboru Yamamoto</searchLink><br /><searchLink fieldCode="AR" term="%22Yasushi+Goto%22">Yasushi Goto</searchLink><br /><searchLink fieldCode="AR" term="%22Shintaro+Kanda%22">Shintaro Kanda</searchLink><br /><searchLink fieldCode="AR" term="%22Yutaka+Fujiwara%22">Yutaka Fujiwara</searchLink><br /><searchLink fieldCode="AR" term="%22Tatsuya+Yoshida%22">Tatsuya Yoshida</searchLink> ) Array ( [Name] => TitleSource [Label] => Source [Group] => Src [Data] => Thoracic Cancer ) Array ( [Name] => Publisher [Label] => Publisher Information [Group] => PubInfo [Data] => Wiley, 2020. ) Array ( [Name] => DatePubCY [Label] => Publication Year [Group] => Date [Data] => 2020 ) Array ( [Name] => Subject [Label] => Subject Terms [Group] => Su [Data] => <searchLink fieldCode="DE" term="%22non‐small+cell+lung+cancer%22">non‐small cell lung cancer</searchLink><br /><searchLink fieldCode="DE" term="%22Adult%22">Adult</searchLink><br /><searchLink fieldCode="DE" term="%22Male%22">Male</searchLink><br /><searchLink fieldCode="DE" term="%220301+basic+medicine%22">0301 basic medicine</searchLink><br /><searchLink fieldCode="DE" term="%22Pulmonary+and+Respiratory+Medicine%22">Pulmonary and Respiratory Medicine</searchLink><br /><searchLink fieldCode="DE" term="%22medicine%2Emedical%5Fspecialty%22">medicine.medical_specialty</searchLink><br /><searchLink fieldCode="DE" term="%22Lung+Neoplasms%22">Lung Neoplasms</searchLink><br /><searchLink fieldCode="DE" term="%22Multivariate+analysis%22">Multivariate analysis</searchLink><br /><searchLink fieldCode="DE" term="%22soluble+PD‐L1%22">soluble PD‐L1</searchLink><br /><searchLink fieldCode="DE" term="%22Pembrolizumab%22">Pembrolizumab</searchLink><br /><searchLink fieldCode="DE" term="%22Antibodies%2C+Monoclonal%2C+Humanized%22">Antibodies, Monoclonal, Humanized</searchLink><br /><searchLink fieldCode="DE" term="%22Gastroenterology%22">Gastroenterology</searchLink><br /><searchLink fieldCode="DE" term="%22Programmed+cell+death+ligand+1%22">Programmed cell death ligand 1</searchLink><br /><searchLink fieldCode="DE" term="%2203+medical+and+health+sciences%22">03 medical and health sciences</searchLink><br /><searchLink fieldCode="DE" term="%220302+clinical+medicine%22">0302 clinical medicine</searchLink><br /><searchLink fieldCode="DE" term="%22Carcinoma%2C+Non-Small-Cell+Lung%22">Carcinoma, Non-Small-Cell Lung</searchLink><br /><searchLink fieldCode="DE" term="%22Internal+medicine%22">Internal medicine</searchLink><br /><searchLink fieldCode="DE" term="%22mental+disorders%22">mental disorders</searchLink><br /><searchLink fieldCode="DE" term="%22medicine%22">medicine</searchLink><br /><searchLink fieldCode="DE" term="%22Humans%22">Humans</searchLink><br /><searchLink fieldCode="DE" term="%22Anti‐PD‐1+antibody%22">Anti‐PD‐1 antibody</searchLink><br /><searchLink fieldCode="DE" term="%22In+patient%22">In patient</searchLink><br /><searchLink fieldCode="DE" term="%22Lung+cancer%22">Lung cancer</searchLink><br /><searchLink fieldCode="DE" term="%22Aged%22">Aged</searchLink><br /><searchLink fieldCode="DE" term="%22Aged%2C+80+and+over%22">Aged, 80 and over</searchLink><br /><searchLink fieldCode="DE" term="%22biology%22">biology</searchLink><br /><searchLink fieldCode="DE" term="%22business%2Eindustry%22">business.industry</searchLink><br /><searchLink fieldCode="DE" term="%22Hazard+ratio%22">Hazard ratio</searchLink><br /><searchLink fieldCode="DE" term="%22Original+Articles%22">Original Articles</searchLink><br /><searchLink fieldCode="DE" term="%22General+Medicine%22">General Medicine</searchLink><br /><searchLink fieldCode="DE" term="%22PD‐L1+TPS%22">PD‐L1 TPS</searchLink><br /><searchLink fieldCode="DE" term="%22Middle+Aged%22">Middle Aged</searchLink><br /><searchLink fieldCode="DE" term="%22Prognosis%22">Prognosis</searchLink><br /><searchLink fieldCode="DE" term="%22medicine%2Edisease%22">medicine.disease</searchLink><br /><searchLink fieldCode="DE" term="%22Survival+Analysis%22">Survival Analysis</searchLink><br /><searchLink fieldCode="DE" term="%22030104+developmental+biology%22">030104 developmental biology</searchLink><br /><searchLink fieldCode="DE" term="%22Oncology%22">Oncology</searchLink><br /><searchLink fieldCode="DE" term="%22030220+oncology+%26+carcinogenesis%22">030220 oncology & carcinogenesis</searchLink><br /><searchLink fieldCode="DE" term="%22biology%2Eprotein%22">biology.protein</searchLink><br /><searchLink fieldCode="DE" term="%22Original+Article%22">Original Article</searchLink><br /><searchLink fieldCode="DE" term="%22Female%22">Female</searchLink><br /><searchLink fieldCode="DE" term="%22Nivolumab%22">Nivolumab</searchLink><br /><searchLink fieldCode="DE" term="%22Antibody%22">Antibody</searchLink><br /><searchLink fieldCode="DE" term="%22business%22">business</searchLink> ) Array ( [Name] => Abstract [Label] => Description [Group] => Ab [Data] => Background Programmed cell death ligand 1 (PD‐L1) is known to have soluble forms aside from its membrane‐bound forms. The aim of this study was to evaluate the predictive and prognostic values of serum soluble PD‐L1 (sPD‐L1) in patients with non‐small cell lung cancer (NSCLC) who were treated with anti‐PD‐1 antibody. Methods A total of 233 patients were enrolled in this study. We assessed the level of serum sPD‐L1 before anti‐PD‐1 antibody treatment (pembrolizumab or nivolumab) and evaluated the correlation with PD‐L1 expression on tumor cells, the response to anti‐PD‐1 antibody treatment, and patient outcome. Results The median serum sPD‐L1 concentration was 67.7 (range, 25 to 223) pg/mL. A weak correlation between serum sPD‐L1 and tumor PD‐L1 expression was observed. The disease control rate in the high sPD‐L1 group (≥90 pg/mL) was significantly lower than that in the low sPD‐L1 group (<br />The PFS and OS of the high sPD‐L1 group were significantly shorter than those of the low sPD‐L1 group. The high level of serum sPD‐L1 was independently associated with a shorter PFS and OS. ) Array ( [Name] => ISSN [Label] => ISSN [Group] => ISSN [Data] => 1759-7714<br />1759-7706 ) Array ( [Name] => URL [Label] => Access URL [Group] => URL [Data] => <link linkTarget="URL" linkTerm="https://explore.openaire.eu/search/publication?articleId=doi_dedup___::19fced2ae8c7ae9ecc4e68e52a492d5d" linkWindow="_blank">https://explore.openaire.eu/search/publication?articleId=doi_dedup___::19fced2ae8c7ae9ecc4e68e52a492d5d</link><br /><link linkTarget="URL" linkTerm="https://doi.org/10.1111/1759-7714.13721" linkWindow="_blank">https://doi.org/10.1111/1759-7714.13721</link> ) Array ( [Name] => Copyright [Label] => Rights [Group] => Cpyrght [Data] => OPEN ) Array ( [Name] => AN [Label] => Accession Number [Group] => ID [Data] => edsair.doi.dedup.....19fced2ae8c7ae9ecc4e68e52a492d5d )
RecordInfo	Array ( [BibEntity] => Array ( [Languages] => Array ( [0] => Array ( [Text] => Undetermined ) ) [PhysicalDescription] => Array ( [Pagination] => Array ( [PageCount] => 11 [StartPage] => 3585 ) ) [Subjects] => Array ( [0] => Array ( [SubjectFull] => non‐small cell lung cancer [Type] => general ) [1] => Array ( [SubjectFull] => Adult [Type] => general ) [2] => Array ( [SubjectFull] => Male [Type] => general ) [3] => Array ( [SubjectFull] => 0301 basic medicine [Type] => general ) [4] => Array ( [SubjectFull] => Pulmonary and Respiratory Medicine [Type] => general ) [5] => Array ( [SubjectFull] => medicine.medical_specialty [Type] => general ) [6] => Array ( [SubjectFull] => Lung Neoplasms [Type] => general ) [7] => Array ( [SubjectFull] => Multivariate analysis [Type] => general ) [8] => Array ( [SubjectFull] => soluble PD‐L1 [Type] => general ) [9] => Array ( [SubjectFull] => Pembrolizumab [Type] => general ) [10] => Array ( [SubjectFull] => Antibodies, Monoclonal, Humanized [Type] => general ) [11] => Array ( [SubjectFull] => Gastroenterology [Type] => general ) [12] => Array ( [SubjectFull] => Programmed cell death ligand 1 [Type] => general ) [13] => Array ( [SubjectFull] => 03 medical and health sciences [Type] => general ) [14] => Array ( [SubjectFull] => 0302 clinical medicine [Type] => general ) [15] => Array ( [SubjectFull] => Carcinoma, Non-Small-Cell Lung [Type] => general ) [16] => Array ( [SubjectFull] => Internal medicine [Type] => general ) [17] => Array ( [SubjectFull] => mental disorders [Type] => general ) [18] => Array ( [SubjectFull] => medicine [Type] => general ) [19] => Array ( [SubjectFull] => Humans [Type] => general ) [20] => Array ( [SubjectFull] => Anti‐PD‐1 antibody [Type] => general ) [21] => Array ( [SubjectFull] => In patient [Type] => general ) [22] => Array ( [SubjectFull] => Lung cancer [Type] => general ) [23] => Array ( [SubjectFull] => Aged [Type] => general ) [24] => Array ( [SubjectFull] => Aged, 80 and over [Type] => general ) [25] => Array ( [SubjectFull] => biology [Type] => general ) [26] => Array ( [SubjectFull] => business.industry [Type] => general ) [27] => Array ( [SubjectFull] => Hazard ratio [Type] => general ) [28] => Array ( [SubjectFull] => Original Articles [Type] => general ) [29] => Array ( [SubjectFull] => General Medicine [Type] => general ) [30] => Array ( [SubjectFull] => PD‐L1 TPS [Type] => general ) [31] => Array ( [SubjectFull] => Middle Aged [Type] => general ) [32] => Array ( [SubjectFull] => Prognosis [Type] => general ) [33] => Array ( [SubjectFull] => medicine.disease [Type] => general ) [34] => Array ( [SubjectFull] => Survival Analysis [Type] => general ) [35] => Array ( [SubjectFull] => 030104 developmental biology [Type] => general ) [36] => Array ( [SubjectFull] => Oncology [Type] => general ) [37] => Array ( [SubjectFull] => 030220 oncology & carcinogenesis [Type] => general ) [38] => Array ( [SubjectFull] => biology.protein [Type] => general ) [39] => Array ( [SubjectFull] => Original Article [Type] => general ) [40] => Array ( [SubjectFull] => Female [Type] => general ) [41] => Array ( [SubjectFull] => Nivolumab [Type] => general ) [42] => Array ( [SubjectFull] => Antibody [Type] => general ) [43] => Array ( [SubjectFull] => business [Type] => general ) ) [Titles] => Array ( [0] => Array ( [TitleFull] => Association between serum level soluble programmed cell death ligand 1 and prognosis in patients with non‐small cell lung cancer treated with <scp>anti‐PD</scp> ‐1 antibody [Type] => main ) ) ) [BibRelationships] => Array ( [HasContributorRelationships] => Array ( [0] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Yuji Matsumoto ) ) ) [1] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Yuichiro Ohe ) ) ) [2] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Hidehito Horinouchi ) ) ) [3] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Ryota Shibaki ) ) ) [4] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Shuji Murakami ) ) ) [5] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Noboru Yamamoto ) ) ) [6] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Yasushi Goto ) ) ) [7] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Shintaro Kanda ) ) ) [8] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Yutaka Fujiwara ) ) ) [9] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Tatsuya Yoshida ) ) ) ) [IsPartOfRelationships] => Array ( [0] => Array ( [BibEntity] => Array ( [Dates] => Array ( [0] => Array ( [D] => 27 [M] => 10 [Type] => published [Y] => 2020 ) ) [Identifiers] => Array ( [0] => Array ( [Type] => issn-print [Value] => 17597714 ) [1] => Array ( [Type] => issn-print [Value] => 17597706 ) [2] => Array ( [Type] => issn-locals [Value] => edsair ) [3] => Array ( [Type] => issn-locals [Value] => edsairFT ) ) [Numbering] => Array ( [0] => Array ( [Type] => volume [Value] => 11 ) ) [Titles] => Array ( [0] => Array ( [TitleFull] => Thoracic Cancer [Type] => main ) ) ) ) ) ) )
IllustrationInfo